Back to top
more

VistaGen Therapeutics (VTGN)

(Delayed Data from NSDQ)

$2.73 USD

2.73
508,116

-0.24 (-8.08%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $2.77 +0.04 (1.47%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 0.00% and -62.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of +1,200.00% and +4.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of 5.88% and 56.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of 8.33% and 785.93%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seer (SEER) delivered earnings and revenue surprises of 8.11% and 26.28%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of 4.65% and 1.13%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 8% and 35%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of -5% and 45.37%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Zymeworks (ZYME) delivered earnings and revenue surprises of 2.50% and 12.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biogen Inc. (BIIB) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Biogen (BIIB) delivered earnings and revenue surprises of 8.22% and 0.92%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy

by Zacks Equity Research

VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 14.63% and 72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Seer (SEER) delivered earnings and revenue surprises of 2.78% and 7.61%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 13.64% and 8.63%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for VistaGen Therapeutics, Inc. (VTGN) points to a 160% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

How Vistagen (VTGN) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Vistagen (VTGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News

by Zacks Equity Research

Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.

Zacks Equity Research

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 16.67% and 41.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioCryst (BCRX) Down as it Discontinues Developing PNH Drug

by Zacks Equity Research

BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.

Zacks Equity Research

Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting

by Zacks Equity Research

Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.

Zacks Equity Research

What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock

by Zacks Equity Research

VistaGen Therapeutics, Inc. (VTGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 0% and 388.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?